LabCorp Launches Neutralizing Antibody Test for COVID-19 Vaccine Development
The test results could potentially be used in the development of COVID-19 vaccines and the screening of convalescent plasma for prophylactic and therapeutic use.
LabCorp announced on June 25, 2020 that it launched a new test that can be used to assess the capacity of antibodies in patient plasma to inhibit the SARS-CoV-2 virus.
The test results could potentially be used in the development of COVID-19 vaccines and the screening of convalescent plasma for prophylactic and therapeutic use, according to a company press release. It will be available to biopharmaceutical companies, hospitals, blood banks, and other plasma-screening facilities.
“By leveraging our drug development and diagnostic capabilities, we are working tirelessly to find solutions to prevent and treat COVID-19,” said Paul Kirchgraber, MD, CEO, LabCorp’s Drug Development business. “The launch of this neutralizing antibody assay is the latest effort in our company’s commitment to accelerate the evaluation of vaccine candidates so that a successful candidate may reach patients sooner.”
Source: LabCorp
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
